Correspondence 0001437749-24-023180 from NovaBay Pharmaceuticals, Inc. (NBY) (CIK 0001389545) (NBY)
NovaBay Pharmaceuticals, Inc. (NBY) (CIK 0001389545)
Date: July 22, 2024 · CIK: 0001389545 · Accession: 0001437749-24-023180
AI Filing Summary & Sentiment
File numbers found in text: 333-280423
Letter
nby20240716_corresp.htm
July 22, 2024
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, DC 20549
Attn: Jimmy McNamara
Re:
NovaBay Pharmaceuticals, Inc. (the “Company”)
Registration Statement on Form S-1
File No. 333-280423
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, the Company hereby respectfully requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-1, as amended (the “Registration Statement”), to become effective as of 5:30 p.m. (Eastern standard time) on Tuesday, July 23, 2024, or as soon as practicable thereafter.
Under separate cover, you will receive today a letter from the representative of the underwriters of the proposed offering joining in the Company’s request for acceleration of the effectiveness of the Registration Statement.
Very truly yours,
NovaBay Pharmaceuticals, Inc.
Show Raw Text
CORRESP 1 filename1.htm nby20240716_corresp.htm July 22, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, DC 20549 Attn: Jimmy McNamara Re: NovaBay Pharmaceuticals, Inc. (the “Company”) Registration Statement on Form S-1 File No. 333-280423 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, the Company hereby respectfully requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-1, as amended (the “Registration Statement”), to become effective as of 5:30 p.m. (Eastern standard time) on Tuesday, July 23, 2024, or as soon as practicable thereafter. Under separate cover, you will receive today a letter from the representative of the underwriters of the proposed offering joining in the Company’s request for acceleration of the effectiveness of the Registration Statement. Very truly yours, NovaBay Pharmaceuticals, Inc. By: /s/ Justin Hall Justin Hall Chief Executive Officer and General Counsel cc: Abby E. Brown, Squire Patton Boggs (US) LLP